TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22153756

Group type: EXPERIMENTAL
Intervention: Personal Patient Profile‐Prostate (decision support system)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Control group (usual patient education)
Number of subjects: 494
Study: 21756812

Group type: EXPERIMENTAL
Intervention: Milrinone (5 mg diluted in 5 ml normal saline inhaled every 8 hours for two days pre-operation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (10 ml normal saline inhaled)
Number of subjects: 30
Study: 19637941

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate 200 mg once/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg twice/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Metoprolol succinate (various doses: 25, 50, 100, 200 mg once/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Carvedilol (various doses: 3.125, 6.25, 12.5, 25 mg twice/day)
Number of subjects: 25
Study: 15809216

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 10357747

Group type: EXPERIMENTAL
Intervention: 60 or 120 mg Fe plus 3.5 mg folic acid weekly for 22 weeks
Number of subjects: 624

Group type: COMPARATOR
Intervention: 5 mg folic acid weekly
Number of subjects: 624
Study: 8540545

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty
Number of subjects: 271

Group type: COMPARATOR
Intervention: Topical medication
Number of subjects: 271
Study: 2036794

Group type: EXPERIMENTAL
Intervention: Copper-bearing Lippes Loop IUD
Number of subjects: 371

Group type: COMPARATOR
Intervention: Standard Lippes Loop IUD
Number of subjects: 371
Study: 7012343

Group type: EXPERIMENTAL
Intervention: Group counseling and education (12 weekly sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational session (for both groups)
Number of subjects: 0
Study: 29401177

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg oral)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 29418049

Group type: EXPERIMENTAL
Intervention: SBIRT program (brief motivational intervention on alcohol use and referral to specialized treatment)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (two leaflets regarding alcohol use and study protocol)
Number of subjects: 200
Study: 26827116

Group type: EXPERIMENTAL
Intervention: Exenatide BID (10μg, 12-30 weeks)
Number of subjects: 4625

Group type: EXPERIMENTAL
Intervention: Exenatide QW (2mg, 24-30 weeks)
Number of subjects: 4625
Study: 24573743

Group type: EXPERIMENTAL
Intervention: TSU-68 + SOX
Number of subjects: 105

Group type: COMPARATOR
Intervention: SOX
Number of subjects: 105
Study: 22663011

Group type: EXPERIMENTAL
Intervention: trametinib (2 mg orally once daily)
Number of subjects: 322

Group type: COMPARATOR
Intervention: chemotherapy (intravenous dacarbazine 1000 mg/m² or paclitaxel 175 mg/m² every 3 weeks)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: trametinib
Number of subjects: 322

Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 322
Study: 20637666

Group type: EXPERIMENTAL
Intervention: EyeSpy with occlusive eyepatch
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: EyeSpy with red-blue dissociative goggles
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Electronic Visual Acuity (EVA) tester and stereopsis testing
Number of subjects: 72

Group type: COMPARATOR
Intervention: Professional eye examination
Number of subjects: 72
Study: 17985560

Group type: EXPERIMENTAL
Intervention: EMLA application four times over a two week period starting with beginning reinnervation of the fingers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 15854844

Group type: EXPERIMENTAL
Intervention: Automatic three-dimensional non-rigid registration scheme using self-organizing maps (SOMs) and radial basis functions (RBFs) for thoracic CT data.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Estimation of lung tumor volumes during radiotherapy treatment planning.
Number of subjects: 15
Study: 12516955

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once daily
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1015
Study: 9660024

Group type: EXPERIMENTAL
Intervention: Laparoscopic (LAP) technique
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional (CON) technique
Number of subjects: 109
Study: 7644247

Group type: EXPERIMENTAL
Intervention: TENS-2 (4 Hz)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TENS-1 (110 Hz)
Number of subjects: 32
Study: 2541193

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg by pressurized aerosol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (postchallenge)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (before challenge)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (before challenge)
Number of subjects: 8
Study: 30565022

Group type: EXPERIMENTAL
Intervention: Doxycycline added to prednisolone
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo plus prednisolone
Number of subjects: 301
Study: 28270216

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (B longum BB536, B infantis M-63, B breve M-16V); 1 sachet/day for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo; 1 sachet/day for 4 weeks
Number of subjects: 40
Study: 25401686

Group type: EXPERIMENTAL
Intervention: Project Connect Online (PCO)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 88
Study: 23486300

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity programme for 25 weeks
Number of subjects: 76
Study: 21483003

Group type: EXPERIMENTAL
Intervention: Decitabine (15 mg/m², intravenously over 4 hours, three times a day for 3 days in 6-week cycles)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 233

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 233
Study: 19037613

Group type: EXPERIMENTAL
Intervention: Lomotil (5 mg diphenoxylate hydrochloride/0.05 mg atropine sulfate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mL water (control group)
Number of subjects: 0
Study: 17237314

Group type: EXPERIMENTAL
Intervention: Vitamin B-12 (2.5, 5, 10, 20, 40, or 80 microg/d) for 30 days
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vitamin B-12 (5.9 microg/d)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vitamin B-12
Number of subjects: 67
Study: 16356087

Group type: EXPERIMENTAL
Intervention: Subcuticular preincision infiltration with 10 ml of bupivacaine (0.5%)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No infiltration (Control Group)
Number of subjects: 39
Study: 11953540

Group type: EXPERIMENTAL
Intervention: Proprioceptive dynamic posture training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise only group
Number of subjects: 0
Study: 9474608

Group type: EXPERIMENTAL
Intervention: Osteotome technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lateral antrostomy (one-step)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lateral antrostomy (two-step)
Number of subjects: 30
Study: 7650933

Group type: EXPERIMENTAL
Intervention: Extraversion and social support
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Neuroticism and stress
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Older age, better education, and social support
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Older age, extraversion, and social support
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 581
Study: 2502837

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg, single oral dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxycillin (3 g) and Probenecid (1 g, single oral dose)
Number of subjects: 100
Study: 1269432

Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion at 20 mug/min in group I
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion at 20 mug/min in group II
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion at higher doses in group III
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion in all groups
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion in group I
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion in group II
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion in group III
Number of subjects: 27
Study: 31770656

Group type: EXPERIMENTAL
Intervention: Hospital and post-discharge quality improvement intervention
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Patient-level digital intervention (optional)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 161
Study: 30797492

Group type: EXPERIMENTAL
Intervention: GC + N (necitumumab 800 mg on days 1 and 8 of a 3-week cycle, gemcitabine 1250 mg/m2 on days 1 and 8, cisplatin 75 mg/m2 on day 1)
Number of subjects: 181

Group type: COMPARATOR
Intervention: GC (gemcitabine 1250 mg/m2 on days 1 and 8, cisplatin 75 mg/m2 on day 1)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: GC + N
Number of subjects: 181

Group type: COMPARATOR
Intervention: GC
Number of subjects: 181
Study: 28183232

Group type: EXPERIMENTAL
Intervention: Triterpenoids and polysaccharide‐enriched Ganoderma lucidum (GL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 25297337

Group type: EXPERIMENTAL
Intervention: Adenosine/verapamil (40 mg orally after converting to sinus rhythm)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Adenosine only (6 mg rapid bolus intravenous injection followed by two repeated doses of 12 mg if necessary)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Adenosine only
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Adenosine/verapamil
Number of subjects: 92
Study: 22420785

Group type: EXPERIMENTAL
Intervention: Podcast
Number of subjects: 40

Group type: COMPARATOR
Intervention: Web
Number of subjects: 40
Study: 21883295

Group type: EXPERIMENTAL
Intervention: Epoxy resin‐based AH Plus sealer
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Polydimethylsiloxane‐based GuttaFlow sealer
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thermafil filling method
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Continuous wave filling method
Number of subjects: 120
Study: 19235368

Group type: EXPERIMENTAL
Intervention: GTC frame
Number of subjects: 84

Group type: COMPARATOR
Intervention: BrainLab thermoplastic mask
Number of subjects: 84
Study: 17284909

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) mouth rinse
Number of subjects: 1101

Group type: COMPARATOR
Intervention: placebo mouth rinse
Number of subjects: 1101
Study: 15097956

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream, applied once daily 5 or 7 times a week for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle cream, applied once daily 5 or 7 times a week for 6 weeks
Number of subjects: 0
Study: 11686827

Group type: EXPERIMENTAL
Intervention: Polylactic‐citric‐acid‐ester (PLA) GTR membrane therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glycolide‐lactic‐copolymer (PGL) GTR membrane therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy control sites (untreated)
Number of subjects: 10
Study: 9219202

Group type: EXPERIMENTAL
Intervention: Helmet (HE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No Helmet (NH)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hot-humid environment (H)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hot-dry environment (D)
Number of subjects: 14
Study: 8424291

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inhalation anaesthesia with isoflurane
Number of subjects: 60
Study: 3690108

Group type: EXPERIMENTAL
Intervention: 12 sessions of combined individual and family psychotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: 12 sessions of dietary advice
Number of subjects: 30
Study: 29793565

Group type: EXPERIMENTAL
Intervention: Topical liposomal thermo-sensitive gel (TLTG)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 81
Study: 25795459

Group type: EXPERIMENTAL
Intervention: Pre-operative occupational therapy intervention (home visit by an occupational therapist)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Health related quality of life and resource use assessments
Number of subjects: 44
Study: 26300269

Group type: EXPERIMENTAL
Intervention: Preoperative treatment with long-acting somatostatin analogue (SSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative SSA treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative pegvisomant treatment
Number of subjects: 0
Study: 23609368

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (200 µg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no intrathecal morphine)
Number of subjects: 56
Study: 20557707

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal midazolam (0.3 mg/kg)
Number of subjects: 0
Study: 19021008

Group type: EXPERIMENTAL
Intervention: 0.5mg/kg ketamine by intravenous route before induction
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.7 mg/kg 0.2% ropivacaine caudally and 2ml normal saline intravenously
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg 0.2% ropivacaine caudally and 0.5mg/kg ketamine by intravenous route
Number of subjects: 60
Study: 16640101

Group type: EXPERIMENTAL
Intervention: lamivudine (3TC; 25 patients)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: pegylated interferon-alpha2a (peg-IFN-alpha2a) 180 mg weekly plus 3TC (23 patients)
Number of subjects: 72

Group type: COMPARATOR
Intervention: pegylated interferon-alpha2a 180 mg weekly plus placebo (24 patients)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: combination therapy (peg-IFN-alpha2a and 3TC)
Number of subjects: 72
Study: 14559932

Group type: EXPERIMENTAL
Intervention: 24-ingredient multivitamin supplementation
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 11050695

Group type: EXPERIMENTAL
Intervention: Onion-olive-oil maceration capsule formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9065544

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Isometric contraction test
Number of subjects: 52
Study: 8351023

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 to 150 mg/d
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 3717537

Group type: EXPERIMENTAL
Intervention: Morphine orally and scopolamine transdermally
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intramuscular morphine and scopolamine
Number of subjects: 38
Study: 29703659

Group type: EXPERIMENTAL
Intervention: Group 1: hot pack and exercises
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Group 2: hot packs, exercises and interferential current
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Group 3: hot packs, exercises and TENS
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Group 4: hot packs, exercises and ultrasound
Number of subjects: 79
Study: 27274218

Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 μg
Number of subjects: 496

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 496
Study: 24411556

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 301
Study: 22775130

Group type: EXPERIMENTAL
Intervention: Use of rumination in response to unpleasant daily events
Number of subjects: 157

Group type: COMPARATOR
Intervention: Lower use of rumination in response to unpleasant daily events
Number of subjects: 157
Study: 20037494

Group type: EXPERIMENTAL
Intervention: Mild-stream bathing
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal bathing
Number of subjects: 14
Study: 18725220

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg daily
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg daily
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 or 15 mg)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 15910347

Group type: EXPERIMENTAL
Intervention: 12% sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8% sevoflurane
Number of subjects: 60
Study: 12803505

Group type: EXPERIMENTAL
Intervention: Polysulfone (PS) membrane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cuprophan (CU) membrane
Number of subjects: 20
Study: 9735583

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine plus clinical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus clinical management
Number of subjects: 0
Study: 7604684

Group type: EXPERIMENTAL
Intervention: Maternal antiphospholipid antibodies (aPA) measured by anticardiolipin antibodies (aCL)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Control group (non-SGA children)
Number of subjects: 414
Study: 2662354

Group type: EXPERIMENTAL
Intervention: Praziquantel 45 mg daily dose
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Praziquantel 60 mg daily dose
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Praziquantel 75 mg daily dose
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Praziquantel 75 mg daily dose in 15-29 year old patients
Number of subjects: 332
Study: 30967307

Group type: EXPERIMENTAL
Intervention: High-animal protein diet (30 E% protein, 40 E% carbohydrates, 30 E% fat)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-plant protein diet (30 E% protein, 40 E% carbohydrates, 30 E% fat)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 37
Study: 29214645

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg.kg‐1
Number of subjects: 304

Group type: COMPARATOR
Intervention: Neostigmine 40 μg.kg‐1 and glycopyrrolate 400 μg
Number of subjects: 304
Study: 27922922

Group type: EXPERIMENTAL
Intervention: Sleep hygiene and relaxation intervention (60-minute educational session, use of storybooks for deep breathing and progressive muscle relaxation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 20
Study: 26481162

Group type: EXPERIMENTAL
Intervention: Presence of LV thrombi detected by cardiac magnetic resonance
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Presence of LV thrombi
Number of subjects: 738
Study: 23313840

Group type: EXPERIMENTAL
Intervention: Needle knife sphincterotomy (NKS)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard cannulation
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study: 20800380

Group type: COMPARATOR
Intervention: Prophylactic cranial irradiation (PCI) to a total dose of 25 Gy in 10 daily fractions (Arm 1)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) to a total dose of 36 Gy (Arm 2 and Arm 3)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) to a total dose of 36 Gy with daily 18 fractions (Arm 2)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) to a total dose of 36 Gy with twice-daily 24 fractions (Arm 3)
Number of subjects: 265
Study: 19245692

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for patients (6-month intervention with 20 group sessions and 12 monthly phone contacts)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Quality improvement-type intervention for physicians (training and performance monitoring)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Usual care for patients (control group)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for patients
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Quality improvement-type intervention for physicians
Number of subjects: 574
Study: 17124621

Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + pindolol (5-HT(1a) antagonist) 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + ketanserin (5-HT(2a) antagonist) 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 16
Study: 15134388

Group type: EXPERIMENTAL
Intervention: Stabilized oral NADH (10 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11772296

Group type: EXPERIMENTAL
Intervention: Tissue factor pathway inhibitor (TFPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9619701

Group type: EXPERIMENTAL
Intervention: Lubeluzole 7.5 mg over 1 h followed by 10 mg/day for up to 5 days
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Lubeluzole (in patients with mild to moderate stroke)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Lubeluzole
Number of subjects: 725
Study: 7930256

Group type: EXPERIMENTAL
Intervention: Enalaprilat (0.6 micrograms/min per 100 ml tissue volume)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: NG‐monomethyl‐L‐arginine (n = 10)
Number of subjects: 30
Study: 3086359

Group type: EXPERIMENTAL
Intervention: Naloxone infusion (8 mg in 1 min followed by 12 mg in 3 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testosterone undecanoate, 40 mg three times a day by mouth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testosterone enanthate 200 mg im every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testosterone enanthate 100 mg im once a week
Number of subjects: 0